Apellis Pharmaceuticals (APLS) stock falls as company's Q3 2024 financials disappoint with lower-than-expected U.S. sales ...

Despite witnessing modest growth in demand over the past three months, Apellis Pharmaceuticals’ complement inhibitor for ...

Apellis Pharmaceuticals (APLS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Apellis stock plunged Tuesday after third-quarter sales of the company's eye drug, Syfovre, widely missed Wall Street's expectations.

In late-session trading, investors were selling out of Apellis, to the point where its price was down by nearly 6%. By ...

and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

Moreover, the outlook for Syfovre is not promising ... Begin your TipRanks Premium journey today. Apellis Pharmaceuticals (APLS) Company Description: Apellis Pharmaceuticals, Inc. is a clinical-stage ...

Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 per ...

Novartis and Apellis Pharmaceuticals have rolled out detailed data on iptacopan and pegcetacoplan, respectively, as they race ...

Q3 2024 Earnings Call Transcript November 5, 2024 Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.32. Operator: Good morning, ladies ...

Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by 7% quarter-over-quarter, with U.S. net product revenue ...